1 | > | 48,537 |
2 | 〉 | 10 |
3 | α= | 8 |
4 | 2°p-timi | 3 |
5 | 68- | 3 |
6 | alpha-error | 3 |
7 | alpha= | 3 |
8 | poroshell | 3 |
9 | -24rnp | 2 |
10 | 250/μl | 2 |
11 | 3-enriched | 2 |
12 | 6º | 2 |
13 | 750g | 2 |
14 | \bar | 2 |
15 | bb- | 2 |
16 | coraje | 2 |
17 | int-2 | 2 |
18 | invaplex | 2 |
19 | kb-r7943 | 2 |
20 | polysaccaride | 2 |
21 | synaptobrevin | 2 |
22 | thiadiazinyl- | 2 |
23 | ≥20°c | 2 |
24 | ⩾25 | 2 |
25 | 'amniocenteses | 1 |
26 | +risperidone | 1 |
27 | -antimir-34a | 1 |
28 | -blocker-resistant | 1 |
29 | -compatibility | 1 |
30 | -dimethylpyridine-2,6-diamine | 1 |
31 | -elevation | 1 |
32 | -enes | 1 |
33 | -methyl-d-glucose | 1 |
34 | -oestradiol | 1 |
35 | -permeability | 1 |
36 | -β-santalol | 1 |
37 | -λ-3 | 1 |
38 | /echocardiography | 1 |
39 | /f1 | 1 |
40 | /metoclopramide | 1 |
41 | /mtor | 1 |
42 | /sulindac | 1 |
43 | 0.28± | 1 |
44 | 0.6262 | 1 |
45 | 1/a2 | 1 |
46 | 10mg/w | 1 |
47 | 150/12.5mg | 1 |
48 | 193± | 1 |
49 | 2',3'- | 1 |
50 | 2-conj-sensitized | 1 |
51 | 27,449.10 | 1 |
52 | 2p-timi | 1 |
53 | 49/ | 1 |
54 | 65yrs | 1 |
55 | 697.32 | 1 |
56 | 9-13.5 | 1 |
57 | acs-2-timi | 1 |
58 | acs-timi | 1 |
59 | activity-below | 1 |
60 | agulation | 1 |
61 | aminophosphine-imidazoline | 1 |
62 | antiparkinsonians | 1 |
63 | apoe3-tr | 1 |
64 | asp-109 | 1 |
65 | bismuth- | 1 |
66 | blocalcin | 1 |
67 | cholerae- | 1 |
68 | cn.cawidth | 1 |
69 | co-limited | 1 |
70 | conditions-with | 1 |
71 | cure:91 | 1 |
72 | depletor | 1 |
73 | dipalladium | 1 |
74 | e-b | 1 |
75 | ed25 | 1 |
76 | encrasicolus | 1 |
77 | exacerbat* | 1 |
78 | exacerbate* | 1 |
79 | g2/n | 1 |
80 | group-p= | 1 |
81 | hedonism | 1 |
82 | hutu | 1 |
83 | ifn-γ+ | 1 |
84 | il-17a+ | 1 |
85 | intensity.parallel- | 1 |
86 | intermediate-2- | 1 |
87 | ip-10δ | 1 |
88 | latelet | 1 |
89 | lbkp | 1 |
90 | ltp-late | 1 |
91 | mdgc-ms/ms | 1 |
92 | npkp | 1 |
93 | oestrone-sulphate | 1 |
94 | oi″ | 1 |
95 | pf-0523655 | 1 |
96 | pl+sb | 1 |
97 | post-cvs/msafp | 1 |
98 | rt-c | 1 |
99 | sero-fibrinous | 1 |
100 | spike- | 1 |
101 | value=0.048 | 1 |
102 | vivelle-dot™ | 1 |
103 | with-one | 1 |
104 | ·4c6f3i3·ch4o | 1 |
105 | ·c4h8o | 1 |
106 | α-error | 1 |
107 | ≤1.67-667 | 1 |
108 | ≤uln | 1 |
109 | ≥12.0 | 1 |
110 | ≥5.3 | 1 |
111 | ≥5/h | 1 |
1 | 'amniocenteses | 1 |
2 | +risperidone | 1 |
3 | -24rnp | 2 |
4 | -antimir-34a | 1 |
5 | -blocker-resistant | 1 |
6 | -compatibility | 1 |
7 | -dimethylpyridine-2,6-diamine | 1 |
8 | -elevation | 1 |
9 | -enes | 1 |
10 | -methyl-d-glucose | 1 |
11 | -oestradiol | 1 |
12 | -permeability | 1 |
13 | -β-santalol | 1 |
14 | -λ-3 | 1 |
15 | /echocardiography | 1 |
16 | /f1 | 1 |
17 | /metoclopramide | 1 |
18 | /mtor | 1 |
19 | /sulindac | 1 |
20 | 0.28± | 1 |
21 | 0.6262 | 1 |
22 | 1/a2 | 1 |
23 | 10mg/w | 1 |
24 | 150/12.5mg | 1 |
25 | 193± | 1 |
26 | 2',3'- | 1 |
27 | 2-conj-sensitized | 1 |
28 | 250/μl | 2 |
29 | 27,449.10 | 1 |
30 | 2p-timi | 1 |
31 | 2°p-timi | 3 |
32 | 3-enriched | 2 |
33 | 49/ | 1 |
34 | 65yrs | 1 |
35 | 68- | 3 |
36 | 697.32 | 1 |
37 | 6º | 2 |
38 | 750g | 2 |
39 | 9-13.5 | 1 |
40 | > | 48,537 |
41 | \bar | 2 |
42 | acs-2-timi | 1 |
43 | acs-timi | 1 |
44 | activity-below | 1 |
45 | agulation | 1 |
46 | alpha-error | 3 |
47 | alpha= | 3 |
48 | aminophosphine-imidazoline | 1 |
49 | antiparkinsonians | 1 |
50 | apoe3-tr | 1 |
51 | asp-109 | 1 |
52 | bb- | 2 |
53 | bismuth- | 1 |
54 | blocalcin | 1 |
55 | cholerae- | 1 |
56 | cn.cawidth | 1 |
57 | co-limited | 1 |
58 | conditions-with | 1 |
59 | coraje | 2 |
60 | cure:91 | 1 |
61 | depletor | 1 |
62 | dipalladium | 1 |
63 | e-b | 1 |
64 | ed25 | 1 |
65 | encrasicolus | 1 |
66 | exacerbat* | 1 |
67 | exacerbate* | 1 |
68 | g2/n | 1 |
69 | group-p= | 1 |
70 | hedonism | 1 |
71 | hutu | 1 |
72 | ifn-γ+ | 1 |
73 | il-17a+ | 1 |
74 | int-2 | 2 |
75 | intensity.parallel- | 1 |
76 | intermediate-2- | 1 |
77 | invaplex | 2 |
78 | ip-10δ | 1 |
79 | kb-r7943 | 2 |
80 | latelet | 1 |
81 | lbkp | 1 |
82 | ltp-late | 1 |
83 | mdgc-ms/ms | 1 |
84 | npkp | 1 |
85 | oestrone-sulphate | 1 |
86 | oi″ | 1 |
87 | pf-0523655 | 1 |
88 | pl+sb | 1 |
89 | polysaccaride | 2 |
90 | poroshell | 3 |
91 | post-cvs/msafp | 1 |
92 | rt-c | 1 |
93 | sero-fibrinous | 1 |
94 | spike- | 1 |
95 | synaptobrevin | 2 |
96 | thiadiazinyl- | 2 |
97 | value=0.048 | 1 |
98 | vivelle-dot™ | 1 |
99 | with-one | 1 |
100 | ·4c6f3i3·ch4o | 1 |
101 | ·c4h8o | 1 |
102 | α-error | 1 |
103 | α= | 8 |
104 | ≤1.67-667 | 1 |
105 | ≤uln | 1 |
106 | ≥12.0 | 1 |
107 | ≥20°c | 2 |
108 | ≥5.3 | 1 |
109 | ≥5/h | 1 |
110 | ⩾25 | 2 |
111 | 〉 | 10 |
1 | exacerbate* | 1 |
2 | exacerbat* | 1 |
3 | il-17a+ | 1 |
4 | ifn-γ+ | 1 |
5 | 2',3'- | 1 |
6 | intermediate-2- | 1 |
7 | 68- | 3 |
8 | bb- | 2 |
9 | cholerae- | 1 |
10 | spike- | 1 |
11 | bismuth- | 1 |
12 | intensity.parallel- | 1 |
13 | thiadiazinyl- | 2 |
14 | 49/ | 1 |
15 | ≥12.0 | 1 |
16 | 27,449.10 | 1 |
17 | cure:91 | 1 |
18 | /f1 | 1 |
19 | int-2 | 2 |
20 | 697.32 | 1 |
21 | 0.6262 | 1 |
22 | 1/a2 | 1 |
23 | -λ-3 | 1 |
24 | ≥5.3 | 1 |
25 | kb-r7943 | 2 |
26 | 9-13.5 | 1 |
27 | ed25 | 1 |
28 | ⩾25 | 2 |
29 | pf-0523655 | 1 |
30 | ≤1.67-667 | 1 |
31 | value=0.048 | 1 |
32 | asp-109 | 1 |
33 | alpha= | 3 |
34 | group-p= | 1 |
35 | α= | 8 |
36 | > | 48,537 |
37 | -antimir-34a | 1 |
38 | e-b | 1 |
39 | pl+sb | 1 |
40 | rt-c | 1 |
41 | /sulindac | 1 |
42 | ≥20°c | 2 |
43 | 3-enriched | 2 |
44 | co-limited | 1 |
45 | 2-conj-sensitized | 1 |
46 | /metoclopramide | 1 |
47 | polysaccaride | 2 |
48 | coraje | 2 |
49 | aminophosphine-imidazoline | 1 |
50 | -dimethylpyridine-2,6-diamine | 1 |
51 | with-one | 1 |
52 | +risperidone | 1 |
53 | -methyl-d-glucose | 1 |
54 | oestrone-sulphate | 1 |
55 | ltp-late | 1 |
56 | 750g | 2 |
57 | 150/12.5mg | 1 |
58 | ≥5/h | 1 |
59 | cn.cawidth | 1 |
60 | conditions-with | 1 |
61 | acs-2-timi | 1 |
62 | 2p-timi | 1 |
63 | 2°p-timi | 3 |
64 | acs-timi | 1 |
65 | poroshell | 3 |
66 | -oestradiol | 1 |
67 | -β-santalol | 1 |
68 | 250/μl | 2 |
69 | hedonism | 1 |
70 | dipalladium | 1 |
71 | g2/n | 1 |
72 | blocalcin | 1 |
73 | synaptobrevin | 2 |
74 | ≤uln | 1 |
75 | agulation | 1 |
76 | -elevation | 1 |
77 | ·4c6f3i3·ch4o | 1 |
78 | ·c4h8o | 1 |
79 | post-cvs/msafp | 1 |
80 | lbkp | 1 |
81 | npkp | 1 |
82 | -24rnp | 2 |
83 | \bar | 2 |
84 | alpha-error | 3 |
85 | α-error | 1 |
86 | depletor | 1 |
87 | /mtor | 1 |
88 | apoe3-tr | 1 |
89 | -enes | 1 |
90 | 'amniocenteses | 1 |
91 | mdgc-ms/ms | 1 |
92 | antiparkinsonians | 1 |
93 | 65yrs | 1 |
94 | encrasicolus | 1 |
95 | sero-fibrinous | 1 |
96 | latelet | 1 |
97 | -blocker-resistant | 1 |
98 | hutu | 1 |
99 | 10mg/w | 1 |
100 | activity-below | 1 |
101 | invaplex | 2 |
102 | /echocardiography | 1 |
103 | -permeability | 1 |
104 | -compatibility | 1 |
105 | 〉 | 10 |
106 | vivelle-dot™ | 1 |
107 | 193± | 1 |
108 | 0.28± | 1 |
109 | oi″ | 1 |
110 | ip-10δ | 1 |
111 | 6º | 2 |